AAV8 Vexosome Vectors Enhance Cell Transduction In Vitro and Outperform Conventional AAV8 Vectors in Liver-Transduction In Vivo in the Presence of Anti-AAV Neutralizing Antibodies

被引：0
|
作者：
Meliani, Amine [1 ,2 ]
Fitzpatrick, Zachary [3 ]
Charles, Severine [2 ]
Mu, Dakai [3 ]
Boisgerault, Florence [2 ]
Maguire, Casey A. [2 ]
Mingozzi, Federico [1 ,2 ]
机构：
[1] Univ Paris 06, Paris, France
[2] Genethon, Evry, France
[3] Harvard Univ, Sch Med, Boston, MA USA
来源：
MOLECULAR THERAPY | 2015年 / 23卷
关键词：
D O I：
10.1016/S1525-0016(16)33920-X
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
311
引用
收藏
页码：S125 / S126
页数：2
相关论文
共 34 条
  • [11] Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by Recombinant AAV2 and AAV8 Vectors in Murine Hepatocytes In Vivo
    Li, Baozheng
    Ma, Wenqin
    Aslanidi, George
    Ling, Chen
    Van Vliet, Kim
    Agbandje-McKenna, Mavis
    Srivastava, Arun
    MOLECULAR THERAPY, 2013, 21 : S208 - S209
  • [12] Effects of Self-Complementarity, Codon Optimization, Transgene, and Dose on Liver Transduction with AAV8
    Bell, Peter
    Wang, Lili
    Chen, Shu-Jen
    Yu, Hongwei
    Zhu, Yanqing
    Nayal, Mohamad
    He, Zhenning
    White, John
    Lebel-Hagan, Deborah
    Wilson, James M.
    HUMAN GENE THERAPY METHODS, 2016, 27 (06) : 228 - 237
  • [13] Differential gene transfer to the choroid plexus after intrathecal delivery or in vitro exposure to AAV5, AAV8, and AAV9 viral vectors
    Churchill, C.
    Schuster, D.
    Schnell, S.
    Kitto, K.
    Peterson, C.
    Vulchanova, L.
    Fairbanks, C.
    JOURNAL OF PAIN, 2014, 15 (04): : S44 - S44
  • [14] Imlifidase treatment facilitates AAV8 liver transduction in SCID mice injected with high dose IVIg
    Erlandsson, E.
    Freiburghaus, C.
    Jain, M. V.
    Nilsson, H. Jernmark
    Lindvall, M.
    Nilsson, S. C.
    Tegui, N. Uzca Prime
    Zhang, X.
    Winstedt, L.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A166 - A166
  • [15] Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques
    Greig, Jenny A.
    Nordin, Jayme M. L.
    Bote, Erin
    Makaron, Leah
    Garnett, Mason E.
    Kattenhorn, Lisa M.
    Bell, Peter
    Goode, Tamara
    Wilson, James M.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2016, 3 : 16079
  • [16] Peptide Ligands Incorporated into the Threefold Spike Capsid Domain to Re-Direct Gene Transduction of AAV8 and AAV9 In Vivo
    Michelfelder, Stefan
    Varadi, Karl
    Raupp, Christina
    Hunger, Agnes
    Koerbelin, Jakob
    Pahrmann, Christiane
    Schrepfer, Sonja
    Mueller, Oliver J.
    Kleinschmidt, Juergen A.
    Trepel, Martin
    PLOS ONE, 2011, 6 (08):
  • [17] OneBac 2.0: Sf9 Cell Lines for Production of AAV1, AAV2, and AAV8 Vectors with Minimal Encapsidation of Foreign DNA
    Mietzsch, Mario
    Hering, Henrik
    Hammer, Eva-Maria
    Agbandje-McKenna, Mavis
    Zolotukhin, Sergei
    Heilbronn, Regine
    HUMAN GENE THERAPY METHODS, 2017, 28 (01) : 15 - 22
  • [18] Analysis of Cross-Reactivity of Anti-AAV Antibodies Elicited in Cynomolgus Monkeys Administered with AAV5, 8, or 9 Vectors
    Dai, Yanshan
    Banks, Glen B.
    Wu, Grace
    Liaw, Jiin-Jia
    Collins, Nathaniel
    Levesque, Paul C.
    Surapaneni, Sekhar
    Jawa, Vibha
    Kozhich, Alexander
    MOLECULAR THERAPY, 2023, 31 (04) : 426 - 427
  • [19] Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
    van Lieshout, Laura P.
    Stegelmeier, Ashley A.
    Rindler, Tara N.
    Lawder, John J.
    Sorensen, Debra L.
    Frost, Kathy L.
    Booth, Stephanie A.
    Bridges, James P.
    Wootton, Sarah K.
    GENE THERAPY, 2023, 30 (3-4) : 236 - 244
  • [20] Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
    Laura P. van Lieshout
    Ashley A. Stegelmeier
    Tara N. Rindler
    John J. Lawder
    Debra L. Sorensen
    Kathy L. Frost
    Stephanie A. Booth
    James P. Bridges
    Sarah K. Wootton
    Gene Therapy, 2023, 30 : 236 - 244
1234